Top AI Companies With Best Stability & Growth (8,588)

Profitability: Company disclosures indicate the first full year of GAAP profitability and multiple consecutive GAAP‑profitable quarters, with expanding operating margins.

Healthy Cash Flow: Reports highlight strong free cash flow in the recent fiscal year and the latest quarter, supporting ongoing investments and capital return.

Future-Ready Strategy: Management emphasizes expanding AI offerings and a usage‑based Operations Cloud package intended to re‑accelerate growth over time, alongside a leadership transition aligned to a new go‑to‑market phase.

Resilient & Sustainable Growth: Reported results show back‑to‑back record revenues with growth across all major lines, even as momentum has moderated. Contributions came from multiple regions, with particular strength cited in the Americas.

Innovation-Driven Growth: Company disclosures highlight significant, ongoing investment to scale AI and modernize platforms, positioning services for future demand. Alliances and technology initiatives are portrayed as key enablers for capturing advisory and assurance opportunities.

Diversified Revenue Streams: Growth is described across Assurance, Advisory, and Tax & Legal, indicating multiple engines rather than reliance on a single line. Regional performance is mixed, but strength in the Americas and EMEA helped offset softness elsewhere.

Strong Revenue Growth: Revenue is accelerating with consistent year-over-year gains and guidance pointing to continued expansion through 2026. Record platform activity and rising deal momentum reinforce top-line trajectory.

Customer Loyalty & Retention: Net dollar retention has improved alongside growth in core genomics customers, indicating expanding usage among existing accounts. Record analyses and repeat adoption across cohorts suggest durable engagement.

Market Expansion: Expansion in the U.S. and APAC and the addition of large integrated health systems support a broader geographic and enterprise footprint. Increasing uptake of newer applications strengthens presence across regions.

Strong Revenue Growth: Recent results show year-over-year increases in revenue and test volumes through 2025 and early 2026. Expanding U.S. adoption and rising Galleri volumes are cited as key contributors.

Strategic Partnerships: Announcements include Epic EHR integration to streamline ordering and results across many health systems, supporting broader access. International and channel collaborations, including Samsung-linked expansion plans, are positioned to extend reach.

Investor Backing & Capital Strength: Post–Illumina spin‑off funding and subsequent equity raises point to a multiyear cash runway. Additional financing provides flexibility to pursue regulatory, reimbursement, and commercialization goals.

Profitability: Reported operating earnings reached $3.6 billion in 2025, a 4% increase over 2024, with the company citing record results in both 2024 and 2025. This upward trend indicates expanding earnings power.

Investor Backing & Capital Strength: Surplus grew to $34.7 billion in 2025 (from $33.3 billion in 2024) alongside continued highest-tier financial strength ratings and record policyowner dividends. These signals point to a robust capital base supporting obligations and growth capacity.

Product Line Growth: Insurance sales rose 14% and annuity sales 40% in 2025, and individual life insurance in force climbed to nearly $1.3 trillion. Such broad-based product momentum underpins expansion across core franchises.

Investor Backing & Capital Strength: In November 2025 the company announced $1.6B in new financing—a $1.1B Term Loan B arranged by JPMorgan plus a ~$500M Series D led by LionTree—at around a ~$5B valuation. These large growth financings are presented as fuel for expansion and acquisitions.

Strong Market Position & Advantage: The take‑private of SP+ created the largest parking network/operator in North America, expanding operations to 4,000+ locations and extensive airport coverage. Additional acquisitions like Oosto and Premier Parking deepen capabilities and broaden distribution.

Market Expansion: Company communications indicate plans to extend its AI checkout‑free platform beyond parking into quick‑service restaurants, fueling, hospitality, and retail. Partnerships such as with Joby on U.S. vertiport sites suggest adjacent‑market expansion.

Investor Backing & Capital Strength: Reports indicate the company closed a $650M Series D in April 2026 at a reported ~$2.2B valuation, following a $260M Series C in April 2025. Management stated the new capital will fund hiring and manufacturing scale-up.

Market Expansion: The company announced a 90,000‑sq‑ft Long Beach, CA campus in February 2025 and plans first Jackal missions to GEO and cislunar space in 2026, extending its footprint and operating regimes. These moves add to Colorado HQ operations and broaden mission reach.

Product Line Growth: After launching Jackal vehicles in 2024, the firm continued Mission X flight testing and plans additional Jackal missions to GEO and cislunar space in 2026. Participation in the Space Force’s VICTUS HAZE mission further expands the active mission slate.

Investor Backing & Capital Strength: Recent announcements cite a $23M Series A extension in May 2025, bringing total disclosed funding to about $60M from investors including Kleiner Perkins, Greenoaks, Meritech, and Spark. These capital signals are described as fueling headcount growth, product development, and go‑to‑market execution.

Innovation-Driven Growth: Product momentum is shown by the 2025 pivot to the Clark AI agent and the “Superblocks 2.0” platform update in April 2026, alongside ongoing release notes through 2026. These launches indicate continued investment in AI, governance, and platform capabilities.

Strong Hiring & Retention: Company materials and listings show open roles and recent postings as of June 2026. This activity suggests headcount expansion rather than contraction.

Investor Backing & Capital Strength: Recent funding rounds include a $75M Series C in February 2026 following a $30M Series B in March 2024, indicating investor confidence and resources to scale.

Strategic Partnerships: Active collaborations are noted with firms such as KPMG, Protiviti, BDO, and CPAmerica, alongside strategic selections by Cherry Bekaert and LSL CPAs.

Innovation-Driven Growth: Product momentum includes launches like Field Orchestrator and claims of achieving AIUC-1 certification, complemented by multiple CPA Practice Advisor Technology Innovation Awards.

Strong Revenue Growth: Evidence indicates the business reported 8x year-over-year growth, millions in ARR, strong month-over-month momentum, and expanding usage alongside a base of 50+ enterprise customers. Expectations to further multiply revenue reinforce a trajectory of accelerated scale.

Investor Backing & Capital Strength: The company raised a $17M Series A followed by a $30M Series B within six months, bringing total funding to $51M from prominent firms including Radical Ventures and Microsoft’s M12. This cadence and investor caliber signal robust capital support for product development and go-to-market expansion.

Innovation-Driven Growth: AI-moderated interviews, agent-led research, and new capabilities such as Visual Intelligence underpin adoption by major enterprises across sectors. Plans to launch an AI-native CXM platform indicate product expansion that broadens use cases and market reach.

Strong Revenue Growth: Reported results show revenue and subscription ARR rising sharply across FY2026 and into Q1 FY2027. Guidance was raised for FY2027, indicating momentum continuing just after year‑end.

Healthy Cash Flow: Operating and free cash flow turned meaningfully positive with margins improving in recent quarters. Management also points to rising subscription ARR contribution margins, indicating better unit economics as scale increases.

Customer Loyalty & Retention: Large‑customer counts continued to climb and subscription dollar‑based net retention is strong. These trends signal expansion within existing accounts alongside new wins.

Strong Revenue Growth: Independent estimates in the snippets indicate ARR rose year over year into 2023 with signals of continued scaling into 2025–2026. This points to an expanding top line despite the absence of official disclosures.

Product Line Growth: Zapier highlights active launches in AI (agents/orchestration) and data products (Tables, Interfaces, Forms, Canvas) alongside new go‑to‑market and RevOps efforts in 2025–2026. These additions broaden use cases and typically align with growth initiatives.

Strong Hiring & Retention: Workforce analytics show the global employee count rising in 2025 versus 2024. This suggests ongoing operational scaling to support product and market expansion.

Investor Backing & Capital Strength: Recent financings include a $56.1M Series C (July 2024) and March 2026 growth-capital from CIBC Innovation Banking, signaling resources to scale product and go-to-market. Feedback suggests this balance-sheet strength underpins continued expansion through 2025–2026.

Product Line Growth: The 2026 launches of ClaimVector (workers’ comp benchmarking) and ClaimVoyant (FNOL triage) show ongoing R&D conversion into new commercial offerings. Additional enhancements and line coverage across underwriting and claims point to an expanding portfolio.

Market Expansion: Named customer additions in 2025 (e.g., Community Health Options; Evolution Risk Partners) and ecosystem placements (e.g., Guidewire Marketplace) indicate widening distribution and adoption. Job postings and an approximately 120-person team further suggest scaling go-to-market capacity.

Investor Backing & Capital Strength: A $372M Series D in June 2024 led by a16z with Sanofi participation provides substantial capital to expand the pipeline and AI capabilities. Reports characterize this as a material valuation step-up and part of a sizable overall funding base.

Strategic Partnerships: A first-of-its-kind AI collaboration with Sanofi and OpenAI and an out‑licensing deal of gusacitinib to Sanofi (up to €545M) indicate strong external validation and access to enterprise-scale deployment. These alliances reinforce market credibility while opening channels for co-development and monetization.

Product Line Growth: Ongoing in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor and an anti‑CD226 program) and 2026 updates showing rapid Phase 1 initiation suggest a broadening and advancing portfolio. The rebrand and model shift aim to support a faster-moving, diversified pipeline across immunology and related areas.

Strategic Partnerships: Recent distribution via a benefits platform (StretchDollar) places the service inside employer channels, signaling expanded go‑to‑market reach. Public partner materials indicate the advocacy service is being offered as an employer perk, broadening access beyond direct-to-consumer.

Investor Backing & Capital Strength: A 2024 Form D filing under the prior legal name and references to a significant seed raise indicate fresh capital to support scaling. The filing signed by the CEO points to formal fundraising intended to fuel growth initiatives.

Market Expansion: Company materials now market consumer outcomes and claim broad family trust, suggesting increased reach since the rebrand. Coverage in a major newspaper feature on using chatbots to fight medical bills elevated visibility in the core problem space.

Investor Backing & Capital Strength: Recent Series A and Series B financings are cited to fund product development and scale to larger institutions, signaling runway and investor confidence.

Strong Revenue Growth: Company materials and coverage indicate revenues, client count, and monthly accounts have increased meaningfully since the 2022 Series A.

Diversified Customer Base: Named relationships span large credit unions, fintech lenders, banks, card issuers, and debt buyers, suggesting broad enterprise traction across creditor types.

Strong Revenue Growth: ARR milestones rising from $100M in early 2024 to $200M by January 2026 indicate rapid top-line expansion. External recognition such as Deloitte’s Technology Fast 500 placements aligns with a multi‑year growth trajectory.

Investor Backing & Capital Strength: A $100 million Series E at a $1.6 billion valuation signals strong investor confidence. This capital provides fuel for continued product development and go‑to‑market expansion.

Market Expansion: International growth is evidenced by new offices in London and Sydney and the signing of the company’s largest customer in Germany. Reported customer counts moving from 2,600+ to 3,500+ teams suggest widening global adoption.

Strong Revenue Growth: Company announcements describe ARR climbing rapidly in 2025, moving from early traction to materially higher recurring revenue within a short window. Public materials describe sustained month‑over‑month gains and a step‑change in scale by late 2025.

Investor Backing & Capital Strength: A late‑2025 Series B led by established venture firms at a substantial reported valuation signals strong external confidence and ample runway. Hiring activity and continued product releases into 2026 reinforce the impression of solid capitalization supporting execution.

Market Expansion: Public claims show customer counts progressing from hundreds earlier in 2025 to four‑figure levels by year‑end, with subsequent materials indicating broader global adoption into 2026. Recognizable enterprise logos and references to usage across many countries suggest widening market reach.

Investor Backing & Capital Strength: Private‑equity firm STG signed a definitive agreement to acquire the company, typically signaling scale and resources to accelerate go‑to‑market and product investment. Prior late‑stage funding and valuation milestones further indicate access to capital and sponsor confidence.

Product Line Growth: The launch of Programmatic CRM with AI agents in 2026 and the expansion of the Da Vinci AI suite into Europe in 2025 show ongoing rollout of new capabilities and features across channels. This sustained shipping cadence suggests continued expansion of the platform’s offering.

Market Expansion: European availability for Da Vinci in 2025 and continued presence in partner content and industry benchmarks in 2026 point to active geographic and ecosystem expansion. Engagement across regions and integrations implies a widening footprint with enterprise buyers.

Innovation-Driven Growth: Public materials cite 5–7 FDA-cleared algorithms, 20+ issued patents, and 4M+ hours of on-body data, plus a December 2025 FDA clearance for the eVO2peak module. The acquisition of physIQ further deepened digital biomarker capabilities and analytics.

Market Expansion: The company reports deployment across 22+ to 26+ countries and states plans to expand access into Europe and Asia by 2026. Integration into Kardigan’s platform is framed as extending reach to more patients and providers.

Strong Hiring & Retention: Hiring posture appears active with a dedicated careers page, multiple open roles on job hubs, and a listed 51–200 (≈80+) employee footprint. LinkedIn activity and recent hiring posts suggest ongoing team growth since early 2025.